Final survival and safety results from a multicenter, open-label, phase 3b trial of erlotinib in patients with advanced nonsmall cell lung cancer
David R. Spigel, Ming Lin, Vincent O'Neill, John D. HainsworthVolume:
112
Year:
2008
Language:
english
Pages:
7
DOI:
10.1002/cncr.23490
File:
PDF, 162 KB
english, 2008